Stocks Health care ELOX
NASDAQ · Health careEloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. reported revenue of $0 in fiscal 2025, down 100.0% from a year earlier. It posted a net loss of $6M. At June 30, 2026 it held $62M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Eloxx Pharmaceuticals, Inc. does
Eloxx Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ELOX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$6M | -$0.49 | n/a |
| 2025 | $6.4M | -$3.1M | -$0.84 | n/a |
| 2023 | $0 | -$17.1M | -$6.63 | n/a |
| 2022 | n/a | -$36.1M | -$16.65 | -$31.9M |
| 2021 | n/a | -$66.7M | -$38.15 | -$35.1M |
| 2020 | n/a | -$34.6M | -$34.54 | n/a |
Latest SEC filings
What Eloxx Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026IPO registration S-1
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 17, 2026Passive stake (5% or more) SCHEDULE 13G
- June 17, 2026Passive stake (5% or more) SCHEDULE 13G
- June 16, 2026Passive stake (5% or more) SCHEDULE 13G
- June 16, 2026Passive stake (5% or more) SCHEDULE 13G
Questions about ELOX
What does Eloxx Pharmaceuticals, Inc. do?
Eloxx Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ELOX.
Is Eloxx Pharmaceuticals, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $6M.
How much revenue does Eloxx Pharmaceuticals, Inc. make?
In fiscal 2025 Eloxx Pharmaceuticals, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Eloxx Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from September 11, 2026.
Similar companies
Follow ELOX
Get an email when Eloxx Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ELOX: get an email when it filesWhere the numbers come from
Financial figures are the values Eloxx Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.